- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
Patent holdings for IPC class C07D 231/02
Total number of patents in this class: 74
10-year publication summary
|
4
|
2
|
5
|
6
|
5
|
6
|
5
|
4
|
4
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2184 |
5 |
| Celgene Corporation | 1388 |
4 |
| Novartis AG | 10346 |
3 |
| National Institute of Biological Sciences, Beijing | 100 |
3 |
| Northwestern University | 3501 |
2 |
| FMC Corporation | 812 |
2 |
| Fox Chase Chemical Diversity Center, Inc. | 15 |
2 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3260 |
2 |
| Verseon Corporation | 9 |
2 |
| Virginia Commonwealth University | 650 |
2 |
| Praxis Precision Medicines, Inc. | 218 |
2 |
| Nuvalent, Inc. | 89 |
2 |
| Merck Sharp & Dohme LLC | 3715 |
2 |
| Genentech, Inc. | 4065 |
1 |
| Janssen Pharmaceutica N.V. | 3233 |
1 |
| Merck Patent GmbH | 5668 |
1 |
| The Board of Trustees of the Leland Stanford Junior University | 6594 |
1 |
| The Regents of the University of Michigan | 4903 |
1 |
| Vertex Pharmaceuticals Incorporated | 1600 |
1 |
| Mayo Foundation for Medical Education and Research | 3349 |
1 |
| Other owners | 34 |